The quest for groundbreaking treatments is driving rapid growth in the Oligonucleotide API Market. These specialized molecules are essential building blocks for developing new drug classes to combat a wide range of diseases. According to a recent analysis, the market is poised for significant expansion, with a projected Compound Annual Growth Rate (CAGR) of 5.60% from 2024 to 2034. This translates to a remarkable surge from a valuation of USD 2.81 billion in 2024 to a staggering USD 4.84 billion by 2034.
Based on an analysis by FMI, the current landscape reveals that over 100 oligonucleotide APIs are advancing through clinical trial phases with regulatory approval on the horizon. Post-approval, there is an anticipated surge in the demand for production capacity, thereby propelling the oligonucleotide API market’s growth trajectory through 2030.
Oligonucleotides are emerging as a prominent class of therapeutics, following in the footsteps of biologics and small molecules. This shift is attributed to their potential to develop drugs at reduced costs, making them a promising avenue for the pharmaceutical industry.
Click Here to Access More Insights on this Market, Get A Sample Report
Apart from immune therapy, microbial and cardiovascular infections, and cancer, oligonucleotide APIs are being tried out to treat neurological disorders like Alzheimer’s as well. However, factors like regulatory complexities and timely delivery of oligonucleotides (amidst COVID-19) are acting as restraints.
Key Takeaways from Oligonucleotide API Marker Study
- Antisense oligonucleotide APIs are anticipated to reach US$ 4 Bn by 2030.
- North America and Europe collectively accounted for more than 47% of revenue share in 2019 while Asia Pacific is expected to grow at the fastest rate in the forecast period.
- Increase in the use of antisense oligonucleotide APIs (especially post-approval from the US FDA in 2016) to boost the market in the forecast period
“Inorganic mode of growth coupled with broad therapeutic applications in gene therapy is expected to bolster the oligonucleotide API market,” says the FMI analyst.
New Product Launches: Key Indicators to Oligonucleotide APIs Market
FMI has analyzed players such as Akcea Therapeutics, Biogen, Sarepta Therapeutics, Jazz Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., and Dynavax Technologies in this report. According to the analysis, these players are consolidating their positions through new product launches.
For instance –
- In March 2020, Dynavax entered into a collaboration with Clover Biopharmaceuticals to develop a vaccine candidate to combat COVID-19. Clover is into advanced evaluation of its Covid-19 S-Trimer, protein-based coronavirus vaccine candidate and Dynavax has its technical expertise along with proprietary toll-like receptor 9 (TLR9) agonist adjuvant, CpG 1018 for executing this.
- Alnylam Pharmaceuticals, Inc., in 2018, launched Givlaari and Onpattro at the commercial level.
Gene Therapy and Oligonucleotide APIs
Synthetic oligonucleotides are being used in gene therapy for inactivating genes that help in propagating the disease. Antisense oligonucleotide APIs are used for disrupting the faulty gene’s transcription.
Also, siRNA could be used for signaling the cell to disrupt faulty mRNA’s translation. Along these lines, Pharmamar, in Jan 2020, signed an agreement with Jazz Pharmaceuticals to sell the API for “lurbinectedin”, one of the late-phase treatments for SCLC (small cell lung cancer) so that the latter could commercialize it.
Get Your Customized Impactful Report Now!
Key Segments of Oligonucleotide API Industry Survey:
by API:
- Antisense Oligonucleotides APIs
- Short Interfering RNA (siRNA) APIs
- Phosphorodiamidate Morpholino Oligonucleotides (PMO) APIs
- MiRNA APIs
- Aptamers APIs
- CpG Oligonucleotides APIs
- Others (ON Conjugates (NP), ShRNA, etc.)
by Marketing Status:
- Marketed
- Clinical Trials (Clinical Phases)
by End User:
- Contract Manufacturing Organizations (CMOs)
- Pharmaceutical Companies
- Biopharmaceutical Companies
- Contract Development & Manufacturing Organizations (CDMOs)
by Region:
- North America Oligonucleotide API Market
- Latin America Oligonucleotide API Market
- Europe Oligonucleotide API Market
- East Asia Oligonucleotide API Market
- South Asia & Pacific Oligonucleotide API Market
- Middle East & Africa (MEA) Oligonucleotide API Market
Key Companies Profiled:
- Jazz Pharmaceuticals, Inc.
- Sarepta Therapeutics
- Biogen
- Dynavax Technologies
- Akcea Therapeutics.
- Alnylam Pharmaceuticals, Inc.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube